Contact this trialFirst, we need to learn more about you.
Behavioural Intervention
Limited-duration Teclistamab for Multiple Myeloma
Recruiting1 awardPhase 2
Philadelphia, Pennsylvania
This trial will study how stopping teclistamab (anti-BCMAxCD3 bispecific antibody) after 6-9 months of treatment affects cancer relapse in patients with a very good partial response. Potential benefits include reduced risk of infection & tumor features that predict durable response.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.